Skip to main content
Premium Trial:

Request an Annual Quote

Anavasi Gets FDA Emergency Use Authorization for Molecular Point-of-Care COVID-19 Test

NEW YORK — The US Food and Drug Administration on Wednesday granted Emergency Use Authorization for Anavasi Diagnostics' molecular point-of-care AscencioDx COVID-19 Test Kit.

The test, which the company submitted to the FDA for EUA about a year ago, uses reverse transcription loop-mediated isothermal amplification to detect SARS-CoV-2 nucleic acid in direct anterior nasal swab specimens. It runs on the company's AscencioDx Molecular Detector, a portable, multiplex testing device that yields results in around 30 minutes, according to Seattle-based Anavasi.

Use of the test is limited to labs CLIA-certified to perform high-, moderate-, or waived-complexity tests, the FDA said. It is also authorized for use at the point of care in settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.